Prostate Cancer - Results from #25040

Method for sampling tissue for research which preserves pathological data in radical prostatectomy - Abstract August 22, 2012

Cut off value of time to prostate specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer - Abstract August 22, 2012

Life after failure of traditional androgen deprivation therapy - Abstract August 22, 2012

Radical prostatectomy versus observation for localized prostate cancer - Abstract August 22, 2012

Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death - Abstract August 22, 2012

Prostate cancer in Denmark 1978-2009 - trends in incidence and mortality - Abstract August 22, 2012

Anxiety and depression among cancer survivors: The role of engagement with sources of emotional support information - Abstract August 22, 2012

Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy - Abstract August 22, 2012

Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial - Abstract August 22, 2012

DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: Investigating causal relationships - Abstract August 22, 2012

The role of bisphosphonate in the treatment of bone metastases from prostate cancer - Abstract August 22, 2012

Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells - Abstract August 22, 2012

Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy - Abstract August 22, 2012

Prostate saturation biopsy following a first negative biopsy: State of the art - Abstract August 22, 2012

Clinical usefulness of bone markers in prostate cancer with bone metastasis - Abstract August 22, 2012

Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis - Abstract August 22, 2012

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual - Abstract August 22, 2012

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer - Abstract August 22, 2012

Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality - Abstract August 21, 2012

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion - Abstract August 21, 2012

Page 1253 of 1436